Search results

Selected filters:

Life Sciences

Article type

Topic

Sector

Regions

889 results found for your search

Sort options
21 June 2019

US strategy for state-owned patents under increasing scrutiny amidst drug price controversies

The government is facing calls to better leverage its own IP in the public interest following revelations about PrEP rights

23 June 2019

Rubio’s Huawei proposal should worry US tech, pharma companies

Letting the executive branch neutralise patents whose owners it doesn’t like would weaken the US patent system and invite retaliation by China

01 July 2019

Slump at the PTAB continues with first half numbers showing big drop in new reviews

Data suggests PTO director Iancu’s IPR reforms are continuing to bite; while despite jump in Q2, district court litigation remains broadly flat for first six months of 2019

08 July 2019

Intel, Alphabet and Qualcomm among big fallers as largest US IP owners cut back on patenting

Latest ranking from IPO of top 300 companies shows an overall decline in the market as the mantra of quality over quantity continues to take effect

13 July 2019

<em>New York Times</em>’ seizure call shows how far the tide is turning against pharma IP

The newspaper’s controversial proposal is stark demonstration of the mounting patent pressure the life sciences sector is under in the US

18 July 2019

Federal Circuit decision shows door not shut on infringement claims under the doctrine of equivalents in ANDA cases

Ruling in UCB v Watson Laboratories provides important strategic guidance on the doctrine for both patent prosecutors and litigators

19 July 2019

Operating company dominance of the patent deals market continues, latest data reveals

Analysis by AST shows Qualcomm, Samsung and TSMC all active, and volumes in line with recent quarterly averages; software still the leading sector in terms of number of transactions

22 July 2019

Brazilian patent office announces measures to tackle massive backlog

Much greater use of foreign search reports is probably the biggest change - but there are doubts as to how effective the measures will be